Lisaftoclax

利沙托克拉

Report date: 2026/05/08 20:02:52
NME

Base Information

Drug NameLisaftoclax
Drug Alias NameListaftoclax力胜克拉利生妥APG-2575
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApoptosis regulator Bcl-2 inhibitors
TargetsApoptosis regulator Bcl-2
Therapy Area/IndicationsSolid tumoursAmyloidosisLupus Erythematosus, Systemic +[20] 
Global Approved IndicationsLeukemia, Lymphocytic, Chronic, B-Cell
Approved Indications in ChinaLeukemia, Lymphocytic, Chronic, B-Cell
Original Approved Country/TerritoryMainland China
Original Approved Date2025/07/08
Country/TerritoryUnited StatesRussian FederationAustralia +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Ascentage Pharma Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesInnovent Biologics IncAscentage Pharma Group InternationalAscentage Pharma Group Inc +[7] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursAmyloidosisLupus Erythematosus, Systemic +[20] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBank